{"id":32020,"date":"2026-09-03T18:39:32","date_gmt":"2026-09-03T13:09:32","guid":{"rendered":"https:\/\/www.medicalbillersandcoders.com\/blog\/?post_type=wpseo_locations&p=32020"},"modified":"2026-09-03T19:56:17","modified_gmt":"2026-09-03T14:26:17","slug":"florida-dermatology-practices-switching-rcm-vendors","status":"publish","type":"wpseo_locations","link":"https:\/\/www.medicalbillersandcoders.com\/blog\/locations\/florida-dermatology-practices-switching-rcm-vendors\/","title":{"rendered":"Why Are Florida Dermatology Practices Switching RCM Vendors Before Year-End Contract Renewals in 2026?"},"content":{"rendered":"\r\n

Florida dermatology practices face a regulatory calendar collision this fall that practices in most other states do not: a federal payment rule, a state Medicaid managed care structure that was rebuilt eight months ago, and the country’s most concentrated Medicare Advantage enrollment season, all landing in the same quarter most vendor contracts require renewal notice.<\/p>\r\n\r\n\r\n\r\n

Nationally, CMS’s CY2027 Physician Fee Schedule proposed rule (CMS-1848-P) is the headline story for dermatology, since it targets the same-day E\/M-plus-procedure billing pattern that drives most encounters in the specialty. Florida practices carry that same exposure, processed through First Coast Service Options (FCSO)<\/strong>, the Medicare Administrative Contractor for Jurisdiction N, which covers Florida, Puerto Rico, and the U.S. Virgin Islands. But Florida dermatology groups are also managing two structural factors most states do not layer on top of it, which is why a routine renewal here carries more weight than the national conversation alone suggests.<\/p>\r\n\r\n\r\n\r\n

A note on where this stands today:<\/strong> CMS-1848-P is a proposed rule, not a final one, and the Modifier -25 mechanics and specialty-level impact figures can still shift before the final rule publishes in November. The Florida-specific factors below, by contrast, are not proposals. SMMC 3.0’s regional restructuring and the Medicare Advantage enrollment calendar are already in effect, which is part of why Florida practices cannot simply wait for federal clarity before making a renewal decision.<\/p>\r\n\r\n\r\n\r\n

The Three Pillars of Florida Dermatology RCM Vendor Readiness Before Year-End Renewal<\/h2>\r\n\r\n\r\n\r\n

This breakdown builds on the framework laid out in our pillar guide, Best Medical Billing Services in the US: The Complete RCM Buyer’s Guide<\/a>, applied specifically to what Florida dermatology practices need to check before a Q4 2026 renewal.<\/p>\r\n\r\n\r\n\r\n

Pillar One: Modifier -25 Exposure Under FCSO’s Jurisdiction N<\/strong> The CY2027 proposed rule’s same-day E\/M-plus-procedure change flows through FCSO the same way it flows through every other Medicare Administrative Contractor, but Florida’s dermatology claim volume is disproportionately exposed given the state’s high concentration of biopsy, destruction, and excision encounters billed alongside evaluation and management visits.<\/p>\r\n

A vendor without a documented plan for how FCSO will apply this change locally has no way to demonstrate readiness before the January 1, 2027 effective date, and Florida’s claim volume through Jurisdiction N means the compounding effect of a missed transition shows up faster than in smaller jurisdictions.<\/p>\r\n\r\n\r\n\r\n

Pillar Two: SMMC 3.0’s Regional Realignment<\/strong> On February 1, 2025, Florida’s Agency for Health Care Administration (AHCA) implemented Statewide Medicaid Managed Care 3.0, restructuring the state from 11 regions to 9 and reassigning Managed Medical Assistance plan contracts across the state. For dermatology practices with meaningful Medicaid volume, this meant re-verifying credentialing and claim routing against a new regional plan map, not a one-time update.<\/p>\r\n

A vendor still billing against legacy SMMC 2.0 region and plan assignments is misrouting claims and generating denials that look like documentation problems but are actually structural, and this is entirely independent of whatever CMS finalizes in November.<\/p>\r\n\r\n\r\n\r\n

Pillar Three: The Snowbird and Annual Enrollment Period Collision<\/strong> Florida carries one of the highest Medicare Advantage penetration rates in the country, and its seasonal population swells every fall as out-of-state patients return for winter, arriving with plan changes made during the Medicare Annual Enrollment Period, which runs October 15 through December 7. That window overlaps almost exactly with the September-through-October notice period most RCM vendor contracts require before a January 1 renewal.<\/p>\r\n

Florida dermatology practices are managing peak eligibility-verification volume and payer-mix churn at the precise moment they need to decide whether their current vendor’s infrastructure can handle it for another full term.<\/p>\r\n\r\n\r\n\r\n

What Happens If You Renew Without an Audit First<\/h2>\r\n\r\n\r\n\r\n
\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n
Renewal Path<\/th>\r\nGeneric RCM Vendor<\/th>\r\nInternal Billing Team<\/th>\r\nMBC Revenue Integrity Partner<\/th>\r\n<\/tr>\r\n<\/thead>\r\n
FCSO Modifier -25 Readiness<\/td>\r\nReactive appeals after denial<\/td>\r\nAd hoc, no jurisdiction-specific tracking<\/td>\r\nGaps quantified and closed before the effective date<\/td>\r\n<\/tr>\r\n
SMMC 3.0 Region Mapping<\/td>\r\nLegacy region assignments still in use<\/td>\r\nManual spreadsheet tracking per plan<\/td>\r\nVerified against current AHCA region and plan structure<\/td>\r\n<\/tr>\r\n
Snowbird\/AEP Eligibility Verification<\/td>\r\nHandled reactively as denials arrive<\/td>\r\nLimited capacity during peak season<\/td>\r\nBuilt into standing seasonal verification protocols<\/td>\r\n<\/tr>\r\n
Contract Terms<\/td>\r\nMulti-year lock-in, exit penalties<\/td>\r\nNot applicable<\/td>\r\nNo long-term lock-in; performance is the retention strategy<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n<\/div>\r\n\r\n\r\n\r\n

The Florida Renewal Decision Timeline<\/h2>\r\n\r\n\r\n\r\n
\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n
Date<\/th>\r\nEvent<\/th>\r\nWhy It Matters to Your Contract<\/th>\r\n<\/tr>\r\n<\/thead>\r\n
September 14, 2026<\/td>\r\nCMS comment deadline on CMS-1848-P<\/td>\r\nLast window to weigh in before federal rule mechanics are finalized<\/td>\r\n<\/tr>\r\n
October 15\u2013December 7, 2026<\/td>\r\nMedicare Annual Enrollment Period<\/td>\r\nPeak plan-change and eligibility-verification volume for Florida’s Medicare Advantage base<\/td>\r\n<\/tr>\r\n
September\u2013October 2026<\/td>\r\nTypical 90\u2013120 day vendor notice window<\/td>\r\nMissing this locks you into another full term through peak season<\/td>\r\n<\/tr>\r\n
November 2026<\/td>\r\nCY2027 PFS final rule expected<\/td>\r\nModifier -25 and conversion factor numbers become fixed<\/td>\r\n<\/tr>\r\n
January 1, 2027<\/td>\r\nFederal effective date<\/td>\r\nNew billing logic applies to every claim from day one<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n<\/div>\r\n\r\n\r\n\r\n

MBC Spotlight: Auditing Before You Sign Anything<\/h2>\r\n\r\n\r\n\r\n

MBC’s Florida dermatology team tracks FCSO’s Jurisdiction N processing behavior, AHCA’s current SMMC 3.0 region and plan structure, and seasonal eligibility-verification demand as three separate, standing disciplines, not a once-a-year checklist. This is the same mechanism-level approach detailed in our review of dermatopathology claim-splitting leakage in Florida<\/a>, applied here to a renewal-timing decision instead of a coding-pattern audit. Our Complimentary Revenue Diagnostic quantifies exactly where your current vendor’s readiness gaps sit against all three Florida-specific pillars, giving your CFO a documented case for renewal, renegotiation, or transition before the notice window closes, without requiring your team to build that audit internally.<\/p>\r\n\r\n\r\n\r\n

With 25+ years of multi-specialty billing experience and a 97% clean claim rate across our Florida dermatology book of business, MBC structures every engagement with no long-term lock-in, so performance, not a contract penalty, is what keeps a client with us. Clients who move to MBC average a 30% reduction in Days in AR within 90 days, and our 98% client retention rate reflects results rather than exit friction built into the contract itself. Practices weighing whether to keep billing in-house through this transition can also review our in-house versus outsourced comparison for Florida dermatology<\/a> before deciding.<\/p>\r\n\r\n\r\n\r\n

Key Takeaways<\/h2>\r\n\r\n\r\n\r\n